Compare Incyte Corporation (INCY) vs Occidental Petroleum Corporation (OXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Occidental Petroleum Corporation — how do they compare? Incyte Corporation trades at $120.81 (market cap $24.54B), while Occidental Petroleum Corporation trades at $58.58 (market cap $55.89B). The key difference: Occidental Petroleum Corporation is far larger — about 2.3× Incyte Corporation's market cap, and Occidental Petroleum Corporation pays a 2% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | OXY | |
|---|---|---|
Market Cap | $24.54B | $55.89B |
Sector | Health | Energy |
52-Week High | $129.93 | $66.24 |
52-Week Low | $81.61 | $38.92 |
Enterprise Value | $20.04B | $74.65B |
Dividend Yield | — | 2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
Occidental Petroleum (OXY) trades at $58.46, down 0.32% on the day, with a bullish technical outlook and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $2.40, surpassing expectations, and targets over $4 billion in annual sustainable cash flow gains by 2030. Valuation ratios like P/E of 16.49 and EV/EBITDA of 5.26 appear reasonable, while profitability metrics such as ROE of 21.46% highlight operational strength. Recent news emphasizes debt reduction and oil price leverage.
OXY offers upside with a consensus price target of $69.33, supported by analyst buy ratings (50%) and institutional optimism. Key risks include oil price volatility and execution of cash flow targets, but fundamentals and sentiment suggest a favorable outlook for investors seeking energy exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Occidental Petroleum Corporation
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2021, the company reported net proved reserves of 3.5 billion barrels of oil equivalent. Net production averaged 1,174 thousand barrels of oil equivalent per day in 2021 at a ratio of 75% oil and natural gas liquids and 25% natural gas.
Read more on OXY →
